Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III Sells 213 Shares of Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 213 shares of the firm’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $48.53, for a total transaction of $10,336.89. Following the completion of the transaction, the chief executive officer now directly owns 40,916 shares in the company, valued at $1,985,653.48. This trade represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $45.63, for a total value of $136,890.00.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The shares were sold at an average price of $60.08, for a total value of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $63.01, for a total value of $126,020.00.

Kewaunee Scientific Stock Down 3.3 %

Shares of NASDAQ:KEQU opened at $44.96 on Tuesday. Kewaunee Scientific Co. has a 1 year low of $30.82 and a 1 year high of $71.33. The company has a market capitalization of $128.36 million, a PE ratio of 7.13 and a beta of 0.71. The business has a fifty day moving average price of $57.26 and a two-hundred day moving average price of $47.64. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.64 and a quick ratio of 2.13.

Kewaunee Scientific (NASDAQ:KEQU) last posted its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 earnings per share for the quarter. The company had revenue of $67.17 million during the quarter. Kewaunee Scientific had a net margin of 9.39% and a return on equity of 25.83%.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research report on Friday, March 14th.

Institutional Investors Weigh In On Kewaunee Scientific

A number of hedge funds have recently modified their holdings of KEQU. Bank of America Corp DE increased its position in Kewaunee Scientific by 2,605.9% in the fourth quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock worth $28,000 after buying an additional 443 shares during the last quarter. IFP Advisors Inc bought a new position in shares of Kewaunee Scientific during the 4th quarter worth $36,000. O Shaughnessy Asset Management LLC increased its holdings in Kewaunee Scientific by 3.3% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 28,008 shares of the technology company’s stock worth $1,733,000 after acquiring an additional 891 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Kewaunee Scientific by 18,000.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock valued at $30,000 after acquiring an additional 900 shares during the period. Finally, Ritholtz Wealth Management lifted its holdings in Kewaunee Scientific by 15.6% during the fourth quarter. Ritholtz Wealth Management now owns 12,619 shares of the technology company’s stock valued at $781,000 after purchasing an additional 1,706 shares during the last quarter. Institutional investors own 32.69% of the company’s stock.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.